tucatinib,trastuzumab
seagen
mountaineer phase 2 trial with tucatinib and trastuzumab in pretreated patients (2 or more prior lines) with her2 positive mcrc. orr: 38.1% (bicr) / dcr: 60%. mdor: 12.4 m. mpfs 8.2 m. mos 24.1 m. 51.3% of patients alive at 24 months.
#wcgic2022 
MD de la UN. Especialista en medicina interna, docencia y oncología.